<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998113</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ADO-2013-153</org_study_id>
    <nct_id>NCT01998113</nct_id>
  </id_info>
  <brief_title>Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. Systematic Review</brief_title>
  <official_title>Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the publication in the New England Journal of Medicine (NEJM) in 2000 of the Langer's
      trial comparing glyburide vs insulin in the treatment of gestational diabetes mellitus (GDM),
      additional studies of oral agents for the treatment of GDM have been published
      (observational, randomized controlled trials (RCT), and trials using other drugs like
      metformin).

      Some meta-analysis to summarize the evidence have been published: Nicholson 2009 (including 4
      RCT addressing different drugs), Dhulkotia 2010 (including 6 RCT addressing different drugs,
      the meta-analysis combining all drugs altogether), Gui 2013 (including 5 RCT addressing
      metformin vs insulin).

      Oral agents are increasingly used for the treatment of GDM. Investigators aim to update the
      evidence on RCTs comparing glyburide and metformin vs insulin or between them and summarize
      this evidence using meta-analysis tools. Specifically, investigators aim at producing
      distinct meta-analyses for each one of the three drug comparisons. This information is not
      available in the literature since the most recent systematic reviews specifically dealing on
      oral agents for the treatment of GDM have addressed a single drug comparison (Gui 2013) or
      have combined different drug comparisons into a single meta-analysis (Dhulkotia 2010)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project involves the systematic review of RCT addressing the use of glyburide or
      metformin for the treatment of GDM. The review will include RCT comparing these drugs versus
      insulin or making direct comparisons between the two oral agents in pregnant women with GDM.

      Investigators have pre-specified a series of maternal and fetal outcomes of interest.

      A comprehensive electronic search strategy will be complemented with a search of
      bibliographies from relevant studies and the contact of authors from the eligible studies
      regarding issues on study design or information on primary outcomes.

      The risk of bias of included studies will be analyzed and this information used to perform
      sensitivity analyses. If possible, data from original studies will be pooled into relative
      risks for dichotomous outcomes and mean differences for continuous outcomes.

      Heterogeneity will be explored for all the analyses. Analyses will be undertaken using a
      fixed effects model that will be repeated using a random effects model in case of substantial
      heterogeneity.

      Results of the systematic review will be published following PRISMA guidance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3rd trimester glycated hemoglobin</measure>
    <time_frame>3rd trimester of pregnancy</time_frame>
    <description>mean difference of 3rd trimester glycated hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total maternal weight gain</measure>
    <time_frame>during pregnancy</time_frame>
    <description>mean difference of total maternal weight gain (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>severe maternal hypoglycemia</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>relative risk of severe maternal hypoglycemia (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>preeclampsia</measure>
    <time_frame>during pregnancy or puerperium</time_frame>
    <description>relative risk of preeclampsia (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cesarean section</measure>
    <time_frame>at the end of pregnancy</time_frame>
    <description>relative risk of cesarean section (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gestational age at birth</measure>
    <time_frame>at birth</time_frame>
    <description>mean difference of gestational age at birth (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>preterm birth</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of preterm birth (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>birthweight</measure>
    <time_frame>at birth</time_frame>
    <description>mean difference of birthweight (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>macrosomia</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of macrosomia (defined as birthweight &gt;=4000 g)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>large-for-gestational age newborn</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of large-for-gestational age newborn (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>small-for-gestational age newborn</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of small-for-gestational age newborn (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neonatal hypoglycemia</measure>
    <time_frame>in the neonatal period</time_frame>
    <description>relative risk of neonatal hypoglycemia (as provided by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>perinatal mortality</measure>
    <time_frame>in the perinatal period</time_frame>
    <description>relative risk of perinatal mortality (as defined by the authors)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin treatment</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>relative risk of insulin treatment (for trials comparing metformin vs glyburide)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>in the period from enrollment to delivery</time_frame>
    <description>mean difference of fasting blood glucose (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial blood glucose</measure>
    <time_frame>in the period from enrollment to delivery</time_frame>
    <description>mean difference of postprandial blood glucose (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal weight gain since enrollment</measure>
    <time_frame>in the period from enrollment to delivery</time_frame>
    <description>mean difference of maternal weight gain since enrollment (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy-induced hypertension</measure>
    <time_frame>during pregnancy</time_frame>
    <description>relative risk of pregnancy-induced hypertension (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>induction of labour</measure>
    <time_frame>at the end of pregnancy</time_frame>
    <description>relative risk of induction of labour (as described by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cord C peptide</measure>
    <time_frame>at birth</time_frame>
    <description>mean difference of cord C peptide (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cord insulin</measure>
    <time_frame>at birth</time_frame>
    <description>mean difference of cord insulin (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal 1 min Apgar</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of abnormal 1 min Apgar (defined as lower than 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal 5 min Apgar</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of abnormal 5 min Apgar (defined as lower than 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obstetric trauma</measure>
    <time_frame>at birth</time_frame>
    <description>relative risk of obstetric trauma (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe neonatal hypoglycemia</measure>
    <time_frame>in the neonatal period</time_frame>
    <description>relative risk of severe neonatal hypoglycemia (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal jaundice</measure>
    <time_frame>in the neonatal period</time_frame>
    <description>relative risk of neonatal jaundice (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>significant respiratory distress</measure>
    <time_frame>in the neonatal period</time_frame>
    <description>relative risk of significant respiratory distress (described as respiratory distress syndrome or requiring respiratory support)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stillbirth</measure>
    <time_frame>in the antenatal period</time_frame>
    <description>relative risk of stillbirth (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal mortality</measure>
    <time_frame>in the neonatal period</time_frame>
    <description>relative risk of neonatal mortality (as defined by the authors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit (NICU) admittance</measure>
    <time_frame>in the neonatal period</time_frame>
    <description>relative risk of NICU admittance (as defined by the authors)</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">2509</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glyburide (Glyburide vs Insulin)</arm_group_label>
    <description>Glyburide vs Insulin trials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin (Glyburide vs Insulin)</arm_group_label>
    <description>Glyburide vs Insulin trials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (Metformin vs Insulin)</arm_group_label>
    <description>Metformin vs Insulin trials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin (Metformin vs Insulin)</arm_group_label>
    <description>Metformin vs Insulin trials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (Metformin vs Glyburide)</arm_group_label>
    <description>Metformin vs Glyburide trials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyburide (Metformin vs Glyburide)</arm_group_label>
    <description>Metformin vs Glyburide trials</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide vs Insulin trials</intervention_name>
    <description>Affecting groups 1 and 2</description>
    <arm_group_label>Glyburide (Glyburide vs Insulin)</arm_group_label>
    <arm_group_label>Insulin (Glyburide vs Insulin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin vs Insulin trials</intervention_name>
    <description>Affecting groups 3 and 4</description>
    <arm_group_label>Metformin (Metformin vs Insulin)</arm_group_label>
    <arm_group_label>Insulin (Metformin vs Insulin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin vs Glyburide trials</intervention_name>
    <description>Affecting groups 5 and 6</description>
    <arm_group_label>Metformin (Metformin vs Glyburide)</arm_group_label>
    <arm_group_label>Glyburide (Metformin vs Glyburide)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with gestational diabetes mellitus requiring drug treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RCT

          -  GDM

          -  comparing Glyburide vs Insulin, Metformin vs Insulin or Metformin vs Glyburide

          -  data on fetal and/or maternal outcomes

          -  full text available

        Exclusion Criteria:

          -  significant overlap with other articles of the same group
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000 Oct 19;343(16):1134-8.</citation>
    <PMID>11036118</PMID>
  </reference>
  <reference>
    <citation>Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. Erratum in: N Engl J Med. 2008 Jul 3;359(1):106.</citation>
    <PMID>18463376</PMID>
  </reference>
  <reference>
    <citation>Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Nov;203(5):457.e1-9. doi: 10.1016/j.ajog.2010.06.044. Epub 2010 Aug 24. Review.</citation>
    <PMID>20739011</PMID>
  </reference>
  <reference>
    <citation>Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol. 2009 Jan;113(1):193-205. doi: 10.1097/AOG.0b013e318190a459. Review.</citation>
    <PMID>19104375</PMID>
  </reference>
  <reference>
    <citation>Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One. 2013 May 27;8(5):e64585. doi: 10.1371/journal.pone.0064585. Print 2013.</citation>
    <PMID>23724063</PMID>
  </reference>
  <reference>
    <citation>Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012 Jan 10;40(3):225-8. doi: 10.1515/jpm-2011-0175.</citation>
    <PMID>22505499</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gestational diabetes mellitus</keyword>
  <keyword>glyburide</keyword>
  <keyword>metformin</keyword>
  <keyword>oral agents</keyword>
  <keyword>insulin</keyword>
  <keyword>outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

